Atezolizumab and Bevacizumab in Hepatocellular Carcinoma

被引：17

作者：

Bomze, David ^{[1
]}

Meirson, Tomer ^{[2
]}

Azoulay, Daniel ^{[2
]}

机构：

[1] Ankara City Hosp, Ankara, Turkey

[2] Yildirim Beyazit Univ, Ankara, Turkey

来源：

关键词：

D O I：

10.1056/NEJMc2021840

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：693 / 694

页数：2

共 5 条

[1] Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Finn, Richard S.
Qin, Shukui
Ikeda, Masafumi
Galle, Peter R.
Ducreux, Michel
Kim, Tae-You
Kudo, Masatoshi
Breder, Valeriy
Merle, Philippe
Kaseb, Ahmed O.
Li, Daneng
Verret, Wendy
Xu, Derek-Zhen
Hernandez, Sairy
Liu, Juan
Huang, Chen
Mulla, Sohail
Wang, Yulei
Lim, Ho Yeong
Zhu, Andrew X.
Cheng, Ann-Lii
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) : 1894 - 1905
[2] Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
Kudo, Masatoshi
[J]. CANCERS, 2020, 12 (05)
[3] A note on quantifying follow-up in studies of failure time
Schemper, M
Smith, TL
[J]. CONTROLLED CLINICAL TRIALS, 1996, 17 (04): : 343 - 346
[4] Reconstructing time-to-event data from published Kaplan-Meier curves
Wei, Yinghui
Royston, Patrick
[J]. STATA JOURNAL, 2017, 17 (04) : 786 - 801
[5] Yau T, 2019, ANN ONCOL, V30, P874